Charles F. Wagner Jr., an officer of Vertex Pharmaceuticals Inc / MA, filed a Form 144 notice on November 12, 2026, proposing the sale of 15,286 shares of Vertex common stock through Fidelity Brokerage Services LLC.

Key Highlights

  • Proposed sale: 15,286 shares of Vertex Pharmaceuticals common stock, with an aggregate market value of $8,374,740.82 according to the filing.
  • Seller: Charles F. Wagner Jr., listed as an Officer of the issuer.
  • Broker: Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield, RI 02917.
  • Shares outstanding: 253,537,674 shares of common stock outstanding at the time of the filing.
  • Rule 10b5-1 plan: The filing indicates a trading plan or instruction date of August 10, 2026.
  • No sales in past 3 months: The filing reports nothing to report under securities sold during the past three months.
  • Exchange: The securities are listed on NASDAQ.

Wagner's Proposed Sale: Acquisition History and Plan Details

According to the filing, the 15,286 shares proposed for sale by Charles F. Wagner Jr. were acquired through a combination of Employee Stock Purchase Plan (ESPP) purchases and restricted stock vestings from the issuer, Vertex Pharmaceuticals Inc / MA (NASDAQ:VRTX). The acquisitions span from November 14, 2023, through May 14, 2025, and include ESPP purchases paid in cash as well as restricted stock vestings received as compensation.

The filing details individual acquisition lots: 19 shares acquired via ESPP on November 14, 2023; 15 shares via ESPP on November 14, 2024; 221 shares from restricted stock vesting on February 20, 2024; 54 shares via ESPP on May 14, 2024; 3,644 shares from restricted stock vesting on February 10, 2025; 2,448 shares from restricted stock vesting on February 17, 2025; 3,533 shares from restricted stock vesting on February 24, 2025; 5,300 shares from restricted stock vesting on February 26, 2025; and 52 shares via ESPP on May 14, 2025.

The filing states the approximate date of sale as November 12, 2026, and notes that a Rule 10b5-1 trading plan or instruction was adopted or given on August 10, 2026. The notice was signed by Margaret Campbell as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Charles F. Wagner Jr. No securities were reported as sold in the three months prior to this notice.

What Was Disclosed

Vertex Pharmaceuticals officer Charles F. Wagner Jr. filed a Form 144 notice proposing to sell 15,286 shares of common stock with an aggregate market value of $8,374,740.82, acquired through ESPP purchases and restricted stock vestings, under a Rule 10b5-1 plan adopted August 10, 2026.